NCI’s Global Cancer Medicine Humanitarian Award awarded to Pat Garcia-Gonzalez

Boston, Massachusetts; USA

The Max Foundation is proud to announce CEO, Pat Garcia-Gonzalez as the recipient of the National Cancer Institute Global Cancer Medicine Humanitarian Award at the U.S. National Cancer Institute 3rd Annual Symposium on Global Cancer Research held in Boston on 25 March 2015.

In the award letter from the National Cancer Institute (NCI), Dr. Edward L. Trimble, MD, MPH, Director of the NCI’s Center for Global Health writes about Pat: “Our global cancer community has been inspired by your outstanding contributions to advancing cancer care equity through The Max Foundation, and as recognition of that work, we would like to honor you.”

Dr. Trimble continues, “Not only have your efforts saved numerous lives, but, to paraphrase Donald Berwick, your contributions go beyond health metrics and health indicators— your contributions will allow mothers and fathers to attend graduations and weddings they would have missed, and grandchildren to know grandparents they might never have known, “and holidays will be taken, and work completed, and books read, and symphonies heard, and gardens tended that, without your work, would never have been.’”

In response to the award, Pat has said, “I am humbled, excited and honored by the recognition given to me thanks to NCI’s Center for Global Health. I see this moment as an opportunity to tell the world about the great collaborations that have made my work possible, as well as a chance to reinforce our collective responsibility around creating solutions to increase global access to treatment, care and support for people living with cancer around the world.”

This is the first Global Cancer Medicine Humanitarian Award to be given at the NCI’s Symposium.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

    The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

    iwCLL to provide training, medical, and programmatic guidance to support implementation of access program for innovative CLL therapy in 29 LMICs over the next three years SEATTLE, Washington – October 10, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients….

  • The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    New initiative expands existing collaboration with Novartis focused on chronic myeloid leukemia and other rare cancers, to support patient access to care for breast cancer, the leading cause of death in women globally

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.